Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.40 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2542108 | 0.98 | CYP1A2 (0.50) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL1531517 | 0.92 | CA12 (0.51) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL654160 | 0.84 | KDM4E (0.51) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL28001857 | 0.83 | CA12 (0.44) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL3954627 | 0.83 | CYP1A2 (0.61) | CYP1A2CTSKFAAHALDH1A1AKR1C1 | |
| Hydrochloric Acid SCHEMBL2991144 | 0.83 | CYP1A2 (0.61) | CYP1A2CTSKFAAHALDH1A1AKR1C1 | |
| SCHEMBL3407690 | 0.82 | CYP1A2 (0.49) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL3087843 | 0.82 | CTSK (0.49) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL10282391 | 0.82 | CA12 (0.44) | CYP1A2CA12CA1CA2CA4 | |
| SCHEMBL10274478 | 0.82 | CA12 (0.56) | CA12CA1CA2CA4CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197850-B1 | DERIVATIVES OF N-PHENYLACETAMIDE, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2013-06-26 | — | — | EP | disclosed |
| EP-2485589-A1 | HETEROARYL BTK INHIBITORS | Biogen Idec MA Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8044082-B2 | N-phenylacetamide inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-10-25 | — | — | US | disclosed |
| WO-2011029043-A1 | HETEROARYL BTK INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100247583-A1 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2197850-A1 | DERIVATIVES OF N-PHENYLACETAMIDE, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | Galderma Research & Development (FR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030747-A1 | DERIVATIVES OF N-PHENYLACETAMIDE, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-12 | — | — | WO | disclosed |
| EP-1490043-A4 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1490043-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082190-A2 | SPIROCYCLIC AMIDES AS CANNABINOID RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247583-A1 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | SOAT1, SOAT2, NAT1 | CYP1A2 530/4885CA12 4594/4885CA1 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.